 |
|
|
| |
Long-term Efficacy Among Participants Switched to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) with Preexisting Resistance and Viral Blips
|
| |
| |
IAS 2021 July 18-22
Kristen Andreatta, Silvia Chang, Madalyn Delaney, Madeleine Willkom, Ross Martin, Sean Collins, Hal Martin, Kirsten L. White
Gilead Sciences, Inc., Foster City, California, USA
|
| |
|
|
|
|
|
